TrialJAMA neurology2022

Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial.

Michael S Rafii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.